Literature DB >> 9703231

Hemodynamic and inotropic effects of milrinone after heart transplantation in the setting of recipient pulmonary hypertension.

E P Chen1, H B Bittner, R D Davis, P Van Trigt.   

Abstract

BACKGROUND: Right ventricular failure remains an important cause of early morbidity and death after heart transplantation and is commonly related to preexistent recipient chronic pulmonary hypertension, which occurs as a result of long-standing congestive heart failure. In this study, the hemodynamic and inotropic effects of milrinone were assessed after bicaval heart transplantation in the setting of monocrotaline pyrrole-induced recipient chronic pulmonary hypertension.
METHODS: Twenty dogs were used for 10 successfully completed transplantation experiments. Recipient animals underwent right atrial injection of 3 mg/kg monocrotaline pyrrole 4 months before transplantation. Hemodynamic and functional data were taken 1 hour after termination of cardiopulmonary bypass and after milrinone infusion. Myocardial function was assessed with load-insensitive means (preload-recruitable stroke work) and pulmonary vascular impedance was calculated with Fourier analysis.
RESULTS: At the time of transplantation, before cardiopulmonary bypass, pulmonary hemodynamic indexes in recipient animals were significantly increased when compared with donors and were further significantly increased after cardiopulmonary bypass. Two animals died after transplantation as a result of acute right ventricular failure. In surviving animals milrinone infusion led to significant increases in right ventricular function, which occurred in association with significant improvements in pulmonary vascular impedance and transpulmonary efficiency.
CONCLUSIONS: In the setting of monocrotaline pyrrole-induced recipient pulmonary hypertension, milrinone was associated with significant improvements in pulmonary vascular impedance, right ventricular function, and transpulmonary efficiency. These data suggest that milrinone is an effective means to improve right ventricular dysfunction and pulmonary vascular efficiency after bicaval heart transplantation in the setting of recipient chronic pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703231

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  6 in total

Review 1.  [Perioperative implications of heart transplant].

Authors:  H K Eltzschig; B Zwissler; T W Felbinger
Journal:  Anaesthesist       Date:  2003-08       Impact factor: 1.041

Review 2.  Heart transplantation research in the next decade--a goal to achieving evidence-based outcomes: National Heart, Lung, And Blood Institute Working Group.

Authors:  Monica R Shah; Randall C Starling; Lisa Schwartz Longacre; Mandeep R Mehra
Journal:  J Am Coll Cardiol       Date:  2012-04-03       Impact factor: 24.094

Review 3.  Inotropes for Preterm Infants: 50 Years on Are We Any Wiser?

Authors:  Aisling A Garvey; Elisabeth M W Kooi; Eugene M Dempsey
Journal:  Front Pediatr       Date:  2018-04-06       Impact factor: 3.418

Review 4.  Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure.

Authors:  Angel Coz Yataco; Melina Aguinaga Meza; Ketan P Buch; Margaret A Disselkamp
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

5.  ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs.

Authors:  Carol Reinero; Lance C Visser; Heidi B Kellihan; Isabelle Masseau; Elizabeth Rozanski; Cécile Clercx; Kurt Williams; Jonathan Abbott; Michele Borgarelli; Brian A Scansen
Journal:  J Vet Intern Med       Date:  2020-02-17       Impact factor: 3.333

6.  Efficacy of Milrinone Plus Sildenafil in the Treatment of Neonates with Persistent Pulmonary Hypertension in Resource-Limited Settings: Results of a Randomized, Double-Blind Trial.

Authors:  Mamdouh El-Ghandour; Bahaa Hammad; Mohamed Ghanem; Manal A M Antonios
Journal:  Paediatr Drugs       Date:  2020-12       Impact factor: 3.022

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.